OTR Therapeutics, LG Chem Partner on China Oncology Assets

OTR Therapeutics has entered into a strategic collaboration with LG Chem to identify, evaluate and develop novel oncology assets originating from China, as both companies seek to expand their access to early-stage cancer programs and advance them for global markets.

The partnership combines OTR Therapeutics’ research and development platform and network within China’s life sciences ecosystem with LG Chem’s global clinical development, regulatory and commercialization capabilities. The companies said the alliance is intended to create a structured pathway for discovering promising oncology programs in China and progressing them toward international development.

Under the collaboration framework, OTR will identify potential oncology assets that align with LG Chem’s strategic priorities. The company will conduct initial technical assessments through its regional scientific network and business development capabilities before the programs move into joint evaluation and licensing discussions.

OTR is expected to lead preclinical and early clinical development for selected programs, drawing on China’s growing biopharmaceutical research ecosystem, development speed and capital-efficient clinical research environment. LG Chem will take a leading role in clinical development outside China, regulatory strategy and commercialization.

The companies did not disclose financial terms for the overall collaboration. However, under individual program agreements, OTR will be eligible to receive upfront payments, as well as development and regulatory milestone payments tied to the progress of selected assets.

OTR will also have the option to participate in global development and obtain a share of global rights for programs that advance into late-stage clinical development. This structure could allow the company to remain involved in the development of successful oncology candidates beyond the early stages while sharing responsibility with LG Chem as programs move toward larger international studies.

The collaboration reflects continued interest among global pharmaceutical and biotechnology companies in China’s expanding drug discovery sector. China has become an increasingly important source of innovative oncology programs, supported by a growing number of biotechnology companies, experienced researchers and clinical development infrastructure.

Dr. Son Ji-woong, president of LG Chem Life Sciences Company, said the agreement will help LG Chem identify and evaluate promising assets emerging from China at an earlier stage.

He said the company aims to strengthen its global competitiveness by securing high-potential programs and advancing them with development partners.

Dr. Zhui Chen, founder and chief executive officer of OTR Therapeutics, said the alliance will combine OTR’s agile research and business development capabilities with LG Chem’s clinical and commercial infrastructure.

The companies expect the long-term collaboration to support a sustainable pipeline of differentiated oncology therapies for patients with significant unmet medical needs. By pairing early-stage discovery capabilities in China with global development and commercialization resources, the partners aim to accelerate the translation of emerging cancer research into medicines for patients worldwide.